Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Translational Development Acquisition Corp.TDAC · Entity 6290 | Director | December 20, 2024 | December 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Translational Development Acquisition Corp.
Report date December 20, 2024 · Filed December 20, 2024
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Traws Pharma, Inc.
Report date August 27, 2020 · Filed August 31, 2020
Section 16 reporting ended · disclosed 2020-08-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,683 |
Reported balance
After 2020-08-27 transaction · row 1
1 source rowRow 1 · 2020-08-27 · Sale · Disposed 527,863 · Balance 16,683 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2020 Filed Aug 31, 2020 20:49 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 527,863 | $0.27 | $143,948.24 |
DisclosureSEC source: 0001179110-20-009439 · edgar.xml · nonDerivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,683 Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:33 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Appreciation Right · Derivative | 125,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008202 · edgar.xml · derivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:57 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseWarrant (right to purchase) · Derivative | 500,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001179110-19-012059 · edgar.xml · derivative · entry 2 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common stock · 500,000 shares Expires 2024-11-25 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:57 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 500,000 | $0.20 | $100,000.00 |
DisclosureSEC source: 0001179110-19-012059 · edgar.xml · nonDerivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,546 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| July 26, 2019 Filed Jul 29, 2019 21:23 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 5,833 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001179110-19-008866 · edgar.xml · derivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,833 Underlying: Common Stock · 5,833 shares Expires 2029-07-26 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 21:29 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 87,500 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001179110-18-010012 · edgar.xml · derivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2028-07-26 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| April 27, 2018 Filed May 1, 2018 22:35 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseWarrant (right to purchase) · Derivative | 282,350 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001179110-18-006019 · edgar.xml · derivative · entry 2 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,350 Underlying: Series B Convertible Preferred Stock · 7,058.75 shares Expires not disclosed F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315). F2 · derivative.expiration_date: The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware. Read SEC document |
| April 27, 2018 Filed May 1, 2018 22:35 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 282,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-006019 · edgar.xml · nonDerivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,182 F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315). Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:04 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 1,500 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-008996 · edgar.xml · derivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2027-06-12 F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 19:03 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 119,048 | $2.10 | $250,000.80 |
DisclosureSEC source: 0001179110-17-006247 · edgar.xml · nonDerivative · entry 1 Reddy E Premkumar · CIK 0001580071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,832 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.